GC
PRTK

Guggenheim Capital’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Guggenheim Capital’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-71,665
Closed -$1.28M – 2821
2017
Q4 		$1.28M Buy
71,665
+23,142
+48% +$483K ﹤0.01% 1939
2017
Q3 		$1.22M Sell
48,523
-8,218
-14% -$191K ﹤0.01% 1984
2017
Q2 		$1.37M Buy
+56,741
New +$1.25M ﹤0.01% 1883

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Guggenheim Capital's PRTK Position: Q1 2018 in Review

Guggenheim Capital sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2018, closing a stake of 71,665 shares — an estimated $1.28M sold.

Guggenheim Capital first reported a position in PRTK in Q2 2017 and held it in 3 quarters. The position peaked at $1.37M in Q2 2017. 114 funds tracked by Wall St. Rank hold PRTK as of Q1 2018.

  • Guggenheim Capital reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Guggenheim Capital sold 71,665 Paratek Pharmaceuticals, Inc. shares in Q1 2018, an estimated $1.28M.
  • Guggenheim Capital first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2017 and held it in 3 quarters.
  • Guggenheim Capital's Paratek Pharmaceuticals, Inc. position peaked at $1.37M in Q2 2017.
  • 114 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2018.

Based on Guggenheim Capital's 13F filing for Q1 2018, filed 15 May 2018.